We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
(+32%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33
Avg Time Held Equity + Options
4.2
quarters
Top 10 Avg Time Held Equity + Options
5.4
quarters
Top 20 Avg Time Held Equity + Options
5.4
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
5.4
quarters
Top 20 Avg Time Held Equity only
5.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$64.1M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$36.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$31.4M |
| 4 |
Puma Biotechnology
PBYI
|
+$17.7M |
| 5 |
Cymabay Therapeutics
CBAY
|
+$15.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$42.4M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$36.7M |
| 3 |
Radius Health, Inc.
RDUS
|
+$29.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$20.9M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.22% |
| 2 | Miscellaneous | 1.22% |
| 3 | Industrials | 0.33% |
| 4 | Consumer Staples | 0.16% |
| 5 | Consumer Discretionary | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
PTLA
126
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $425K | 0.02% |
7,870
| – | – |
2017 Q1
2 quarters
|
|
|
ZSAN
127
DELISTED
Zosano Pharma Corporation
ZSAN
| $412K | 0.02% |
714
| – | – |
2017 Q1
2 quarters
|
|
128
CALL
Molina Healthcare
MOH
$10.7B
| $345K | 0.01% |
+50,000
| New | +$3.25M |
2017 Q3
0 quarters
|
|
|
ICPT
129
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $283K | 0.01% |
+250,000
| New | +$26.9M |
2017 Q3
0 quarters
|
|
130
HUTCHMED
HCM
$2.38B
| $273K | 0.01% |
+10,000
| New | +$245K |
2017 Q3
0 quarters
|
|
131
Grace Therapeutics
GRCE
$42.5M
| $267K | 0.01% |
3,887
| – | – |
2013 Q3
16 quarters
|
|
132
CALL
DELISTED
Sage Therapeutics
SAGE
| $178K | 0.01% |
215,000
-60,000
| -22% | -$4.71M |
2017 Q1
2 quarters
|
|
133
Senseonics Holdings Inc
SENS
$489M
| $160K | 0.01% |
+2,500
| New | +$130K |
2017 Q3
0 quarters
|
|
134
PUT
Alnylam Pharmaceuticals
ALNY
$30.4B
| $45K | ﹤0.01% |
+420,000
| New | +$35.8M |
2017 Q3
0 quarters
|
|
135
CALL
Incyte
INCY
$22.6B
| $35K | ﹤0.01% |
+100,000
| New | +$12.7M |
2017 Q3
0 quarters
|
|
136
CALL
Ionis Pharmaceuticals
IONS
$7.26B
| $24K | ﹤0.01% |
+60,000
| New | +$3.14M |
2017 Q3
0 quarters
|
|
137
ANI Pharmaceuticals
ANIP
$1.69B
| – | – |
-125,399
| Closed | -$5.87M | – |
|
138
Arrowhead Research
ARWR
$8.58B
| – | – |
-847,458
| Closed | -$1.37M | – |
|
139
DELISTED
bluebird bio
BLUE
| – | – |
-1,544
| Closed | -$2.1M | – |
|
140
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-3,106
| Closed | -$465K | – |
|
141
Edwards Lifesciences
EW
$49.8B
| – | – |
-18,264
| Closed | -$719K | – |
|
142
EyePoint Inc
EYPT
$286M
| – | – |
-114,956
| Closed | -$1.97M | – |
|
143
Icon
ICLR
$12.7B
| – | – |
-5,187
| Closed | -$507K | – |
|
|
144
Jazz Pharmaceuticals
JAZZ
$14.1B
| – | – |
-85,572
| Closed | -$13.3M | – |
|
|
145
Molina Healthcare
MOH
$10.7B
| – | – |
-8,140
| Closed | -$530K | – |
|
146
Outlook Therapeutics
OTLK
$142M
| – | – |
-5,237
| Closed | -$837K | – |
|
147
CALL
Ultragenyx Pharmaceutical
RARE
$1.51B
| – | – |
-100,000
| Closed | -$6.21M | – |
|
|
148
Sarepta Therapeutics
SRPT
$1.84B
| – | – |
-1,089,961
| Closed | -$36.7M | – |
|
149
UnitedHealth
UNH
$340B
| – | – |
-28,480
| Closed | -$5.28M | – |
|
150
Xenon Pharmaceuticals
XENE
$3.47B
| – | – |
-723,853
| Closed | -$2.28M | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2017 Portfolio in Review
As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors deployed $142M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.
- Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
- Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
- Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
- Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
- Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.
Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.